Tumour-associated Macromolecules
The occurrence of members of this first group is better understood as a consequence of the great sensitivity of radioimmunoassay. They are classified as 'antigens' only in the sense that they are detected by immunological procedures but need not elicit a specific immunological response in the host. Most of them are oncofetal antigens, ie, are found in the normal fetus as well as in a variety of tumours, and also occur in body fluids and in patients with nonneoplastic disease. This phenomenon, considered to be shown by all human and experimental tumours, is called 'retrogenetic expression' (Stonehill and 102 Bendich, 1970) . The persistence of these substances in some fetal tissues up to the later stages of fetal life may induce immunological tolerance. The presence of immunologically identical material in some normal adult tissues indicates that their presence in abnormal cells is not the result of the re-emergence of a process that has been completely suppressed in normal cells. Changes in the levels in body fluids, while not specific for cancer, may indicate the presence of a tumour with a degree of certainty related to the actual level found.
'Tumour-specific' Antigens By contrast, the 'tumour-specific' antigens are detected by less sensitive methods than those based on radioimmunoassay. With the acquisition of more precise immunochemical information in the future, it may be found that their production is not limited solely to neoplastic cells. However, at the present time they are generally found only in neoplastic tissue and blood from tumour-bearing hosts in whom they induce antibody and/or cell-mediated immune reactions. These substances cannot be detected in fetal tissues or normal adult tissue with the presently available techniques.
Whereas the major clinical usefulness of the tumour-associated macromolecules may be in the area of tumour detection, the tumour-specific antigens may be of importance in relation to tumour therapy as well as detection.
Tumour-associated Macromolecules ('Antigens')
Many oncofetal antigens have now been described in association with human tumours (table I). The fetal pancreatic antigen described by Banwo Versey, and Hobbs (1974) Kayser, Eklund, and Luning (1973) have now been added to those initially reviewed by and more recently by several groups of workers (Abelev, 1974; Ruoslahti, Pihko, and Seppala, 1974; Hakkinen, 1974; Neville and Laurence, 1974; Terry, Henkart, Coligan, and Todd, 1974) . Two of them, the carcinoembryonic antigen and alpha-fetoprotein, have been the subjects of much work in recent years and will be discussed in detail as illustrative examples of the concept and, despite their relative non-specificity, of the role of these substances in clinical oncology.
CARCINOEMBRYONIC ANTIGEN (CEA) The carcinoembryonic antigen (CEA) was described originally by Gold and Freedman (1965) who considered that it occurred solely in primary and metastatic human colorectal carcinomas and in the alimentary tract, liver, and pancreas of the human fetus between the ages of 2 and 6 months. While the initial radioimmunoassay studies of its occurrence in plasma confirmed this apparent specificity for colorectal and pancreatic tumours (Thomson, Krupey, Freedman, and Gold, 1968) , many further investigations have now shown that CEA (or CEA-like material) is present in normal adult tissues as well as in numerous varieties of tumours and the plasma from such patients, and in diverse body fluids including those of normal subjects (see review by Neville and Laurence, 1974 (Krupey, Gold, and Freedman, 1968; Newman, Petras, Hamilton, Hager, and Hansen, 1972; Coligan, Henkart, Todd, and Terry, 1973; Turberville, Darcy, Laurence, Johns, and Neville, 1973; Banjo, Shuster, and Gold, 1974) . Differences in amino acid composition of CEA of different origins are minor, suggesting that, as with other sialo-glycoproteins, there is a constant polypeptide portion but variation in the outer parts of the oligosaccharide chains. The finding of identical unique N-terminal amino acid sequences in several CEA preparations (Terry, Henkart, Coligan, and Todd, 1972; Chu, Bhargava, and Harvey, 1974) supports this view.
The protein part is thought to contain a single chain containing six intramolecular disulphide bridges (Thomas, Westwood, and Foster, 1974) whose cleavage leads to a large decrease in immunogenicity as measured by radioimmunoassay. Similar losses occur following degradation with dilute acid (Westwood, Thomas, and Foster, 1974b) or proteolytic enzymes (pepsin, subtilisin) .
The carbohydrate part of CEA is probably made up of about 40-50 oligosaccharide units each containing 13-15 monosaccharides, joined to the protein via asparagine-N-acetyl-glucosamine linkages and rich in fucose, galactose, and N-acetyl-glucosamine. Mannose and smaller amounts of N-acetyl-galactosamine and sialic acid are also found. Removal of about 50% of the carbohydrate by the Smith degradation procedure does not change the immunogenicity of the material as judged by radioimmunoassay (Westwood, Bessell, Bukhari, Thomas, and Walker, 1974a (Denk, Tappeiner, Eckerstorfer, and Halzner, 1972) .
Carcinoembryonic antigen or CEA-like materials occur in a wide variety of normal and pathological tissues and body fluids (Khoo, Warner, Lie, and Mackay, 1973; Neville and Laurence, 1974 (Terry et al, 1974) . In contrast, some of the known CEA-reacting molecules are definitely chemically different from 'authentic colonic CEA' on the basis of their higher molecular weight. These include substances found in the urine of normal persons and bladder cancer patients, in semen and in benign breast cyst fluid (Neville, Nery, Hall, Turberville, and Laurence, 1973; Vandevoorde, Newman, Fresolone, MacDonald, and Hansen, 1973; Fleisher, Oettgen, Breed, Robbins, Pinsky, and Schwartz, 1974; Nery, Barsoum, Bullman, and Neville, 1974a; Nery, James, Barsoum, and Bullman, 1974b; Coombes, Hall, and Neville, 1975) . It has also been suggested that CEA isolated from breast carcinomas is different from colonic CEA (Chu, 1974) . 'From data compiled by .
Clinical application
wide variety of histogenetically different tumours, and with numerous inflammatory, regenerative, and other non-neoplastic states (table II) . Many studies have shown that raised plasma levels are principally a function of the site and extent of tumour spread or of the tumour volume (Laurence, Stevens, Bettelheim, Darcy, Leese, Turberville, Alexander, Johns, and Neville, 1972) which, together with the many 'false positive' situations, limit severely its role for the diagnosis or differential diagnosis of early neoplasia.
Patient surveillance At present the greatest clinical value of CEA measurement is to facilitate the earlier detection of recurrent or metastatic colorectal carcinoma (Mach, Jaeger, Berthelot, Ruegsegger, Loosli, and Pettarel, 1974; Mackay, Patel, Carter, Stevens, Laurence, Cooper, and Neville, 1974; Sorokin, Sugarbaker, Zamcheck, Pisick, Kupchik, and Moore, 1974;  (table IV) . Therefore, the serial assay of plasma CEA seems to represent a valuable addition to the armamentarium available to the clinician to detect recurrent and metastatic tumours of colorectal origin. Vincent and Chu (1973) have presented similar data for patients with bronchial carcinoma, and we have seen similar trends in occasional patients with breast and urothelial carcinoma (Coombes et al, 1975; figs 3 and 4 of radio-and/or chemotherapy. Objective remissions induced by various methods of treating mammary, bronchial, and occasionally colorectal carcinomas can be associated with a simultaneous decline to normal levels of plasma CEA (Vincent and Chu, 1973; Cooper and Mackay, personal communication; Skarin, Delwiche, Zamchek, Lockich, and Frei, 1974; Steward, Nixon, Zamcheck, and Aisenberg, 1974) . Occasionally the clinical evidence of remission precedes the fall in plasma levels (Chu and Nemoto, 1973) ; such a delayed fall may be related to radiation-or drug-induced necrosis resulting in increased release of CEA from the tumour (Bagshawe, Rogers, Searle, and Wilson, 1973; . In the absence of a therapeutic response rising CEA titres are generally observed, particularly with bronchial and colorectal carcinomas. Chemotherapy of these tumours may achieve steady levels of CEA for a short period of several months before there is an 'escape' with dramatically rising titres associated with the terminal phase of the disease (Cooper and Mackay, 1974) .
ALPHA-FETOPROTEIN (AFP)
Alpha-fetoprotein (AFP), originally described by Abelev, Perova, Khramkova, Postnikova, and Irlin (1963) , is a product of the yolk sac, fetal liver and gastrointestinal tract which appears in the fetal blood (Gitlin, 1971) . Early studies of plasma levels in adults suggested a specific increase in patients with primary cancer of the liver, but subsequent work with more sensitive methods has disproved any such tumour specificity. It is now known that a variety of inflammatory and regenerative conditions may be associated with increased blood levels (see below). Chemistry Alpha-fetoprotein is an oxi-globulin with a molecular weight of the order of 64 000 (Nishi, 1970) . Approximately 4% of the molecule is carbohydrate, with hexose, hexosamine, and sialic acid occurring in a ratio of 2.2:1.2:0.9 (Ruoslahti et al, 1971) . As with CEA, there is evidence that AFP from different sources may vary slightly in composition. While this is largely due to differing amounts of sialic acid (Purves, Van der Merwe, and Bersohn, 1970; Zimmerman and Madappally, 1973) , two different molecular species have recently been identified by affinity chromatography (Smith and Kelleher, 1973) .
Current evidence suggests that AFP in fetal serum and the serum of hepatoma-bearing subjects are chemically identical; the total number of amino acids is the same and peptide maps are identical (Nishi, 1970; Ruoslahti, Seppala, Pihko, and Vuopio, 1971) . Alpha-fetoprotein binds oestradiol-17, but not testosterone, and this may represent an important physiological function (Uriel, 1974) . The possibility has also been raised that AFP may play an immunosuppressive role .
Sources
The principal source of AFP during fetal life is the liver. It appears to be an intracellular product of the hepatocytes which is released into the blood stream; it is also present in high concentration in the amniotic fluid.
After birth plasma AFP levels decline progressively until the age of 2 years, after which the low level (2-6 ± 16 ,ug/l) is maintained. A small rise may occur subsequently after the age of 60 years (Masseyeff, Gilli, Krebs, Bonet, and Zrihen, 1974) . Consequently, as with CEA (vide supra), although the production of AFP falls significantly after birth, it is not completely suppressed.
Other sources of AFP are discussed below.
Clinical applications
The most important current clinical application of AFP assays is in obstetrics. Raised levels are found in the amniotic fluid in association with fetuses having neural tube defects or a 45/XO chromosomal constitution (Allan, Ferguson-Smith, Donald, Sweet, and Gibson, 1973; Brock, Bolton, and Monaghan, 1973; Leek, Ruoss, Kitan, and Chard, 1973; Seller, Campbell, Cottart, and Singer, 1973; Seller, 1974) . In addition, raised AFP titres occur in the plasma of pregnant women with Rh-immunization or diabetes (Seppala and Ruoslahti, 1974) , and also in conjunction with fetal distress (Seppala and Ruoslahti, 1973) . A detailed consideration of these aspects is beyond the scope of this article. New developments may be found in the proceedings of a recent conference Purves, Manso, and Torres (1973) believe that the tumour's ability to synthesize and release AFP is set at a particular fixed rate at an early stage. The plasma level of AFP is unrelated to tumour size; not all tumour cells seem to produce AFP.Nodularand poorly differentiatedtumours tend to be associated with the highest levels (Purves et al, 1973) . However, in studies of liver regeneration in animals, serum AFP levels are related to the number of proliferating cells (Wepsic, Bernstein, and Sell, 1974) . Extensive screening of gold miners who have a high frequency of hepatomas has failed to reveal a phase when AFP is raised in the plasma in the absence of a clinically detectable tumour (Purves et al, 1973) , so that its role in early diagnosis is limited. Recent work has also shown that the plasma level is raised in non-neoplastic liver disease and hence it is not 'cancer specific' so that its differential diagnostic role also is limited (table V) . From clinical and experimental studies it would appear that raised levels in non-neoplastic liver disease reflect the response of the liver to the injury rather than the severity of damage and occur in association with the regenerative phase of these disorders. With complete recovery, the levels return to normal values (Sell, Nichols, Becker, and Leffert, 1974; Silver et al, 1974) . Thus, the presence of tumour may be distinguished from some forms of liver damage by the inexorable rise of AFP as shown by serial estimations.
Therapy for hepatomas is usually ineffective, but (McIntire, Vogel, Princler, and Patel, 1972) .
Malignant teratomas
In man and animals the rare yolk sac tumours produce raised AFP levels in the plasma (Ballas, 1972) ; benign teratomas, in contrast, are associated with normal levels (Hooghe, Zeicher, Sobis, and Vandeputte, 1974) . Our own preliminary studies of the occurrence of AFP in the plasma of patients with gonadal malignant teratomas are shown in table VI. Raised levels appear to be independent of tumour differentiation and to be less stage-dependent than CEA levels (table VII) . To date, none of the combined tumours in our series' has been associated with raised levels although this is known to occur (Braunstein, Mclntire, and Waldmann, 1973) . Successful surgical therapy results in a return of the AFP levels to the normal range (table VI) , and preliminary data suggest that sequential AFP levels may be useful as a guide to the efficacy of chemoand/or radiotherapy. The incorporation of measurements of other tumour index substance, eg, human chorionic gonadotrophin, may be highly beneficial as different populations of tumour cells producing different products can show differential therapeutic responses (Braunstein et al, 1973) .
Serial AFP assays may help in the earlier detection of recurrence or metastases, although recurrence can occur without a concomitant rise in AFP levels 'That is mixed tumours containing elements of teratoma and seminoma. (Esterhay, Shapiro, Sutherland, Mclntire, Wiernik, 1973) .
and
Other tumours A variety of other tumours may be associated with raised AFP levels, particularly in the presence of hepatic metastases. A recent study of CEA and AFP levels in the blood of patients with gastric carcinomas, has shown that some tumours produce one or other antigen, and a few produce both, so that determining both can increase the detection rate (Ravry, McIntire, Moertel, Waldmann, Schutt, and Go, 1974) .
Cancer-specific Antigens
This group of materials is still regarded as having a high degree of specificity for tumours. They are possibly of greater biological importance than the tumour-associated macromolecules because of their influence upon the tumour-bearing subject's immune system. Only one of these materials has been studied chemically in any significant detail, namely, the cancer basic protein. The remainder have been identified immunologically and are now the subject of intensive chemical investigation.
CANCER BASIC PROTEIN
In an attempt to develop a reliable quantitative method of measuring cell-mediated immune reactions in vitro Field and Caspary (1970) devised the macrophage electrophoretic mobility (MEM) test. They noted that subjects with malignant tumours exhibited lymphocyte sensitization to a basic protein of myelin, encephalitogenic factor (EF). Further studies revealed that a basic protein, present in human tumours, the so-called cancer basic protein, could also produce this phenomenon; it is chemically related to EF but is not identical with it.
Chemistry
Current studies indicate that cancer basic protein (CaBP) is a 'cancer-specific' antigen which is common to all human malignant neoplasms (Carnegie, Caspary, and Field, 1973; Dickinson, Caspary, and Field, 1973) . It has basic properties and a molecular weight of the order of 16 000 (Dickinson and Caspary, 1973) . After tryptic digestion, an active fragment is released composed solely of amino acids, less than 4000 daltons in molecular weight and containing one tryptophan residue essential for activity in the MEM test (Dickinson and Caspary, 1973) .
This tumour antigen is considered to reside on the cell surface and approximately 104 molecules of antigenically active material are present per cell . It is thought to be absent from normal cells which, however, contain a related material (Dickinson, McDermott, Smith, and Caspary, 1974 (Field, Hughes, and Caspary, 1973b) .
Clinical applications
The MEM test and its clinical significance have now been assessed by several workers (Goldstone, Kerr, and Irune, 1973; Pritchard, Moore, Sutherland, and Joslin, 1973a, b) and some technical improvements resulting in increased sensitivity have been made (Pritchard et al, 1973b (Hellstrom and Hellstrom, 1974 ) based on the fact that lymphocytes from a tumour-bearing subject will exert toxic effects on the cells of that patient's tumour and those of tumours of the same organ from other patients but not on cells from tumours arising in other tissues, eg, reactions will occur between lymphocytes of a breast cancer subject and all breast tumour cells but not against colorectal carcinoma cells or those from a sarcoma or melanoma.
Evidence from experimentally induced and human tumours suggests that these antigens are shed by the tumour cells into the blood where they may exist free or as antigen-antibody complexes; the latter may account for the inhibition of lymphocyte cytotoxicity in vitro seen with advancing disease (so-called 'blocking factors') (Currie, 1973; Embleton, 1973; Baldwin, Embleton, Price, and Vose, 1974) . What effect this phenomenon has upon the progression of the disease in vivo remains to be clarified.
At present, therefore, these types of antigens are regarded as being tumour-specific because they have not so far been detected in non-neoplastic tissues, and as organ specific with respect to the origin of the tumour. Recent work has shown that experimental tumours, in addition to possessing tumour-specific transplantation (rejection) antigens, also possess embryonic antigens at the cell surface which are immunogenic and which exhibit organ specificity (Baldwin et al, 1974) . Consequently, it is important now to ascertain if the organ-specific antigens of human tumours are also embryonic in type like CEA and AFP although differing from the latter in their immunogenic action on the host. The future possibility of isolating such organ specific antigens in pure form and developing sensitive methods for detecting their presence in body fluids or their effects upon the immune system could have farreaching implications in the clinical management and detection of neoplasia.
Summary
The concept of tumour-specific antigens is constantly undergoing reappraisal with the development of more sensitive methods for their detection. This has resulted in the finding that the many 'new' antigens produced by human tumours or materials immunologically closely related to them are also present in non-neoplastic tissues, albeit in small amounts. However, other antigens still appear to exist almost entirely in or on tumour cells so that the antigens of human tumours may be subdivided into either tumour-associated macromolecules or tumourspecific antigens.
The elucidation of the chemical nature of the tumour-specific antigens may result in important advances in cancer diagnosis and therapy. As many are organ specific, it should be possible to evolve test systems which will enable tumours to be diagnosed and located before they become apparent clinically.
On the other hand the tumour-associated macromolecules, of which the oncofetal antigens are the principal examples, are found in elevated amounts in some non-neoplastic disorders. It is now clear that serial estimation of the levels of these macromolecules is of considerably more diagnostic value than single random measurements. Current work is establishing their value in the detection of recurrent and metastatic tumours before they become apparent by other methods, which is probably their most important role, and also their value as aids to monitor therapeutic efficacy.
The future use of both types of antigen may unfold a new era in cancer detection and therapy but many basic chemical and immunological studies are needed before their clinical use can be fully defined.
